Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ENDOTHELIAL DYSFUNCTION AND ROLE NITRATES AND BETA-BLOCKERS IN ITS CORRECTION IN ISCHEMIC HEART DISEASE

https://doi.org/10.20996/1819-6446-2016-12-2-234-238

Full Text:

Abstract

The role of endothelial dysfunction in the pathogenesis of ischemic heart disease and some other cardiovascular diseases is considered. The endothelial dysfunction takes place at the earliest stages of diseases. The interaction of vasodilator and vasoconstrictor factors produced by vascular endothelium is discussed. The treating effect of some medicinal products (nitrates, beta-blockers and others) is analyzed from the point of view of their correcting influence on endothelial function.

About the Author

A. N. Britov
State Research Centre for Preventive Medicine, Moscow
Russian Federation


References

1. Lüscher T.F., Vanhoutte P.M. The Endothelium: Modulator of Cardiovascular Function. Boca Raton, FL: CRC Press; 1990.

2. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;299:373-6.

3. Palmer R.M.J., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.

4. Palmer R.M.J., Ashton D.S., Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-6.

5. Palmer R.M.J., Rees D.D., Ashton D.S., Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988; 153: 1251-6.

6. Feihl F., Liaudet L., Waeber B. The Macrocirculation and Microcirculation of Hypertension. Current Hypertension Reports 2009; 11(3): 182-9.

7. Ilyina AE, Kljukvina NG, Alexandrova EN, et al. Atherosclerotic vascular lesion in systemic lupus erythematosus and antiphospholipid syndrome in men. Klinicheskaya meditsina 2006; 84 (4): 23-8. In Russian (Ильина А. Е., Клюквина Н. Г., Александрова Е. Н., и др. Атеросклеротическое поражение сосудов при системной красной волчанке и антифосфолипидном синдроме у мужчин. Клиническая медицина 2006;84(4): 23-8).

8. Campeau L. Grading of angina pectoris. Circulation 1976;54:5223.

9. Fischenko AL, Vertkin AL, Martynov AI. Nitrates in the treatment of ischemic heart disease. Kardiologiia 1996; 36 (6): 88-95. In Russian (Фищенко А.Д., Верткин А.Л., Мартынов А.И. Применение нитратов в лечении ишемической болезни сердца. Кардиология 1996; 36(6):88-95).

10. Heidenreich P.A., McDonald K.M., Hastie T., et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281: 1927-9.

11. Belousov YB Isosorbide-5-mononitrate: Clinical Pharmacology. Novyy Meditsinskiy Zhurnal 1997; 3: 3-6. In Russian (Белоусов Ю.Б. Изосорбид-5-мононитрат: клиническая фармакология. Новый Медицинский Журнал 1997; 3:3-6).

12. Pucshin YM, Nikolaeva EP, Shubin SK et al. Clinical evaluation of efficacy retard forms of isosorbide- 5-mononitrate in patients with chronic ischemic heart disease. Kardiologiia 1999; 2: 45-9. In Russian (Пущин Ю.М., Николаева Е.П., Чурина С.К., и др. Клиническая оценка эффективности препарата ретардной формы изосорбид-5-мононитрата у больных хронической ишемической болезнью сердца. Кардиология 1999; 2:45-9).

13. Parker I.O. “IS-5-MN Study Group”: Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993; 72: 871-6.

14. Kubli S., Feihl F., Waeber B. Beta-blocade with nebivolol enhances the acetylcholine-induced cutaneus vasodilation. Clin Pharmacol Therap 2001; 69: 238-44.

15. Stoleru L, Wijns W, van Eyll C, et al. Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol. J Cardiovasc Pharmacol 1993,22(2):183-90.

16. Palazzuoli A, Calabria P., Verzuri M.S., Auteri A. Carvedilol: something else than a simple beta-blocker? Eur Rev Med Pharmacol Sci 2002;6(6):115-26.

17. Das Gupta P, Broadhurst P, Raftery EB et al. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 66: 1118-23.

18. Broeders MAW, Doevendans PA, Bas CAM. A Third-Generation b-Blocker That Augments Vascular Nitric Oxide Release. Circulation 2000;102:677.

19. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.

20. Van N, Amerongen GP, Vermeer MA, et al. Simvastatin improves disturbed endothelial barrier function. Circulation 2000;102:2803-09.

21. Britov AN, Gomazkov OA. Biochemical, structural and clinical analysis of pleiotropic effects of statins. Kardiovaskulyarnaya Terapiya i Profilaktika 2009; 5: 92-102. In Russian (Бритов А.Н., Гомазков О.А. Биохимический, структурный и клинический анализ плейотропных эффектов статинов. Кардиоваскулярная Терапия и Профилактика 2009;5: 92-102).


For citation:


Britov A.N. ENDOTHELIAL DYSFUNCTION AND ROLE NITRATES AND BETA-BLOCKERS IN ITS CORRECTION IN ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2016;12(2):234-238. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-2-234-238

Views: 398


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)